Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen

Clinical Cancer Research

Volumn 4, Issue 6, 1998, Pages 1451-1457

  Warner, Ellen ^a,d   Hedley, David ^a   Andrulis, Irene ^a   Myers, Robert ^a   Trudeau, Maureen ^a   Warr, David ^a   Pritchard, Kathleen I ^a   Blackstein, Martin ^a   Goss, Paul E ^a   Franssen, Edmee ^a   Roche, Kathie ^a   Knight, Shelagh ^a   Webster, Sheila ^a   Fraser, Ruth Anne ^a   Oldfield, Stephanie ^a   Hill, Wendy ^b   Kates, Robert ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Knoll Pharma Inc   (Canada)

^c Analytical Solutions Inc   (United States)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DEXVERAPAMIL; NORVERAPAMIL;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; FEMALE; FLOW CYTOMETRY; HUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; P-GLYCOPROTEIN; VERAPAMIL;

EID: 17644440990     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Harris, J., Morrow, M., and Norton, L. Malignant tumors of the breast. In: V. T. DeVita Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, 5th ed., pp. 1557-1616. Philadelphia: Lippincott-Raven, 1947.
2. Chen, C. J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., and Roninson, I. B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47: 381-389, 1986.
3. Goldstein, L. J., Galski, H., Fojo, A., Asselain, B., Beuzebocu P., Magdelenat, H., and Vielh, P. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst., 81: 116-124, 1989.
4. Van der Valk, P., Kalken, C. K., Ketelaars, H., et al. Distribution of multidrug-resistance associated P-glycoprotein in normal and neoplastic human tissues. Ann. Oncol., 1: 56-64, 1990.
5. Chevillard, S., Pouillart, P., Beldjord, C., Asselain, B., Beuzeboc, P., Magdelenat, H., and Vielh, P. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer (Phila.), 77: 292-300, 1996.
6. Giaccone, G., Linn, S. C., and Pinedo, H. M. Multidrug resistance in breast cancer: mechanisms, strategies. Eur. J. Cancer, 31A: 515-517, 1995.
7. Verrelle, P., Meissonnier, F., Fonck, Y., Feillel, V., Dionet, C., Kwiatkowski, F., Plagne, R., and Chassagne, J. Clinical relevance of immunohistochemical detection of multidrug resistance to P-glycoprotein in breast carcinoma. J. Natl. Cancer Inst., 83: 111-116, 1991.
8. Veneroni, S., Zaffaroni, N., Dardone, M. G., Benini, E., Villa, R., and Silvestrini, R. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur. J. Cancer, 30A: 1002-1007, 1994.
9. Schneider, J., Bak, M., Efferth, T. L., Kaufmann, M., Mattern, J., and VoIm, M. P-glycoprotein expression in treated and untreated human breast cancer. Br. J. Cancer, 60: 815-818, 1989.
10. Ro, J., Sahin, A., Ro, J. Y., Fritsche, H., Hortobagyi, G., and Blick, M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum. Pathol., 21: 787-791, 1990.
11. 99mTc-Sestamibi efflux and therapeutic response in patients with advanced breast carcinoma. Proc. Am. Assoc. Cancer Res., 37: 310, 1996.
12. Uziely, B., Deflator-Weiss, E., Lenz, H. J., et al. Paclitaxel in refractory breast cancer: response correlates with low levels of MOR gene expression. Proc. Am. Soc. Clin. Oncol., 13: 75, 1994.
13. Stewart, D. J., and Evans, W. K. Non-chemotherapeutic agents that potentiate chemotherapy efficacy. Cancer Treat. Rev., 16: 1-40, 1989.
14. Thurlimann, B., Kroger, N., Greiner, J., Mross, K., et al. Dexverapamil to overcome epirubicin resistance in advanced breast cancer. J. Cancer Res. Clin. Oncol., 121 (Suppl. 3): R3-R6, 1995.
15. Demicheli, R., Jirillo, A., Bonciarelli, G., Lonardi, F., Balli, M., and Bandello, A. 4′-Epidoxorubicin plus verapamil in anthracycline-refractory cancer patients. Tumori, 75: 245-247, 1989.
16. Schumacher, K., Ladda, E., Buhl, K., et al. Reversal of multidrug resistance by R-verapamil. In: M. Eichelbaum, H-P. Hirth, K. Schumacher, and U. Traugott (eds.), Dexverapamil: Circumventor of Multidrug Resistance, pp. 57-64. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1993.
17. Maulard, C., Marie, J-P., Delanian, S., and Housset, M. Clinical effects on CA 15-3 level of cyclosporin A as a chemosensitiser on chemoresistant metastatic breast cancer. Eur. J. Cancer, 29A: 480, 1993.
18. Christen, R. D., McClay, E. F., Plaxe, S. C., et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. J. Clin. Oncol., 11: 2417-2426, 1993.
19. DeGregario, M. W., Ford, J. M., Benz, C. C., and Wieb, V. J. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J. Clin. Oncol., 7: 1359-1364, 1989.
20. Haussermann, K., Benz, B., Gekeler, V., Schumacher, K., and Eichelbaum, M. Effect of verapamil erantiomers and major metabolites on the cytotoxicity of vincristine and dannomycin in human lymphoma lines. Eur. J. Clin. Pharmacol., 40: 53-59, 1991.
21. Plum, J. A., Milroy, R., and Kaye, S. B. The activity of verapamil as a resistance modifier in vitro in drug-resistant human tumour cell lines is not stereospecific. Biochem. Pharmacol., 39: 787-792, 1990.
22. Miller, A. B., Hoogstraten, B., Staguet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
23. Harapat, S. R., and Kates, R. E. Simultaneous quantitation of verapamil and its active metabolite, norverapamil. J. Chromatogr., 181: 484-489, 1980.
24. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
25. Chen, C. J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., and Roninson, I. B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47: 381-389, 1986.
26. Lee, P. D., Noble-Topham, S. E., Bell, R. S., and Andrulis, I. L. Quantitative analysis of multidrug resistance gene expression in human osteosarcomas. Br. J. Cancer, 74: 1046-1050, 1996.
27. Akiyama, S., Fojo, A., Hanover, J. A., Pastan, I., and Gottesman, M. M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat. Cell Mol. Genet., 11: 117-126, 1985.
28. Xie, S. X-Y., Robb, D., Chow, S., and Hedley, D. W. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia (Baltimore), 9: 1882-1887, 1995.
29. Mross, K., Bohn, C., Edler, L., Jonat, W., Queisser, W., Heidemann, E., Goebel, M., and Hossfeld, D. K. Randomized Phase II study of single-agent epirubicin ± verapamil in patients with advanced metastatic breast cancer. Ann. Oncol., 4: 45-50, 1993.
30. Wishart, G. C., Bissett, D., Jodrell, D., et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J. Clin. Oncol., 12: 1771-1777, 1994.
31. Motzer, R. J., Lyn, P., Fischer, P., Lianes, P., Ngo, R. L., Cordon-Cardo, C., and O'Brien, J. P. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J. Clin. Oncol., 13: 1958-1965, 1995.
32. Wilson, W. H., Bates, S. E., Fojo, A., et al. Controlled trial of dexverapamil, a modulator of multidrug resistance in lymphomas refractory to EPOCH chemotherapy. J. Clin. Oncol., 13: 1995-1004, 1995.
33. Wilson, W. H., Jamis-Dow, C., Bryant, G., Balis, F. M., Klecker, R. W., Bates, S. E., Chabner, B. A., Steinberg, S. M., Kohler, D. R., and Wittes, R. E. Phase I and pharmacokinetic study of the multidrug resistance modulator: dexverapamil with EPOCH chemotherapy. J. Clin. Oncol., 13: 1985-1994, 1995.
34. Elliot, H. L., and Meredith, P. A. Clinical pharmacological studies with R-verapamil. In: M. Eichelbaum, H-P. Hirth, K. Schumacher, and U. Traugott (eds.), Dexverapamil: Circumventor of Multidrug Resistance pp. 43-50. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1993.
35. Trump, D. L., Smith, D. C., Ellis, P. G., Rogers, M. P., Schold, S. C., Winer, E. P., Panella, T. J., Jordan, V. C., and Fine, R. L. High-dose oral tamoxifen, a potential multidrug resistance reversal agent: Phase I trial in combination with vinblastine. J. Natl. Cancer Inst., 84: 1811-1816, 1992.
36. Chabner, B. A., Bates, S. E., Fojo, A. T., Wittes, R. E., Bryant, G. A., Herdt, J. R. L., and Wilson, W. H. Studies of drug resistance in malignant lymphoma. Int. J. Radiat. Oncol. Biol. Phys., 27 (Suppl.): 124, 1993.
37. Schneider, E., Horton, J. K., Yang, C. H., Nakagawa, M., and Cowan, K. H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54: 152-158, 1994.
38. Filipits, M., Suchomel, R. W., Dekan, G., Haider, K., Depisch, D., Valdimarsson, G., Huber, H., and Pirker, P. MRP and MDR1 gene expression in primary breast carcinomas. Proc. Am. Assoc. Cancer Res., 37: 309, 1996.
39. Kim, R., Hirabayashi, N., Nishiyama, M., Saeki, S., Toge, T., and Okada, K. Expression of MDR1, GST-π and topoisomerase II as an indicator of clinical response to Adriamycin. Anticancer Res., 11: 429-431, 1991.
40. Molina, R., Osterrich, S., Zhou, J. L., et al. Glutathione transferase GST-π in breast tumours evaluated by three techniques. Dis. Markers, 11: 71-82, 1993.
41. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2: 811-814, 1996.
42. Bargou, R. C., Wagener, C., Bommert, K., Mapara, M. Y., Daniel, P. T., Arnold, W., Dietel, M., Guski, H., Feller, A., Royer, H. D., and Dorken, B. Overexpression of the death-promoting gene bax-a which is down-regulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumour growth in SCID mice. J. Clin. Invest., 97: 2651-2659, 1996.
43. Scheithauer, W., Schenk, T., and Czejka, M. Pharmacokinetic interaction between epirubicin and the multidrug resistance reversing agent D-verapamil. Br. J. Cancer, 68: 8-9, 1993.
44. Berg, S. L., Tolcher, A., O'Shaughnessy, J. A., Denicoff, A. M., Noone, M., Ognibene, F. P., Cowan, K. H., and Balis, F. M. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J. Clin. Oncol., 13: 2039-2042, 1995.
45. 99mTc-Sestamibi scan in patients with breast carcinoma. Proc. Am. Assoc. Cancer Res., 37: 310, 1996.